mk-2206 and Carcinoid-Tumor

mk-2206 has been researched along with Carcinoid-Tumor* in 1 studies

Other Studies

1 other study(ies) available for mk-2206 and Carcinoid-Tumor

ArticleYear
Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
    Anti-cancer drugs, 2013, Volume: 24, Issue:1

    Carcinoids are neuroendocrine malignancies characterized by their overproduction of various bioactive hormones that lead to the carcinoid syndrome. We have shown previously that AKT serves as a key regulator of growth and phenotypic expression of tumor markers in carcinoids by the genetic depletion of AKT expression. However, no small-molecule inhibitor of AKT kinase activity has been developed until recently. MK-2206, a novel allosteric inhibitor of AKT, is currently undergoing clinical trials for the treatment of solid tumors. In this study, we explored the effect of MK-2206 on carcinoid cell proliferation and bioactive hormone production in vitro in two carcinoid cell lines - pancreatic carcinoid BON and bronchopulmonary H727. Treatment with MK-2206 effectively suppressed AKT phosphorylation at serine 473 and significantly reduced cell proliferation in a dose-dependent manner. Most importantly, MK-2206 treatment resulted in a significant reduction in ASCL1, CgA, and NSE expression, collectively recognized as markers of neuroendocrine tumor malignancy. Furthermore, MK-2206-treated cells showed an increase in levels of cleaved PARP and cleaved caspase-3, with a concomitant reduction in levels of Mcl-1 and XIAP, indicating that the antiproliferative effect of MK-2206 occurs through the induction of apoptosis. In conclusion, MK-2206 suppresses carcinoid tumor growth, and alters its neuroendocrine phenotype, indicating that this drug may be beneficial for patients with carcinoid syndrome. These studies merit further clinical investigation.

    Topics: Allosteric Regulation; Antineoplastic Agents; Apoptosis; Bronchial Neoplasms; Carcinoid Tumor; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-akt

2013